News

­

Quark announces patent approval for Methods for treating eye disorders

September 1st, 2015|

The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss […]

Quark will present at Eurotides 2015, Maritim proArte Hotel, Berlin, Germany ,16-18 Nov 2015

August 23rd, 2015|

http://www.informa-ls.com/event/eurotides2015

Quark announces patent approval for Compositions and methods for treatment of ear disorders

July 28th, 2015|

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need […]

Quark announces patent approval for therapeutic uses of inhibitors of RTP801

June 16th, 2015|

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.

Read More…

Quark announces patent approval for double stranded RNA compounds to RhoA and use thereof

June 2nd, 2015|

The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences […]

Quark announces patent approval for oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases

April 14th, 2015|

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient […]

Quark will present at 2015 American Transplant Congress, May 5, 2015

April 5th, 2015|

Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk

E. Squiers,1 B. Irish,1 D. Odenheimer,1 S. Erlich,1 J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.

1Quark, Fremont
2UCSF, SF
3U of Barcelona, BCN, Spain.

Meeting: 2015 American Transplant Congress

Abstract number: 448

Keywords: Cadaveric organs, Graft function, Kidney transplantation, Outcome

 

http://www.atcmeetingabstracts.com/abstract/relationship-between-delayed-graft-function-dgf-severity-and-predicted-dgf-risk/

Quark will present at TIDES 2015, at the Town and Country Hotel in San Diego, CA, May 3-6, 2015

April 3rd, 2015|

Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 […]

Quark will present at The 7th GTC Ocular Disease Drug Discovery Conference. San Diego, CA. March 18-19, 2015.

February 18th, 2015|

A Synthetic Chemically Modified siRNA Targeting Caspase 2 as a Therapeutic Agent for Ocular Neuroprotection

https://www.gtcbio.com/conferences/ocular-diseases-drug-discovery-speakers

Quark announces patent approval for Methods for delivery of siRNA to the spinal cord and therapies arising therefrom

December 2nd, 2014|

The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver […]